Stroke
Conditions
Keywords
Stroke, Quality of life, Spasticity
Brief summary
The use of robotic technology for the treatment of gait in neurological pathologies has provided different results in scientific evidence. In patients with some types of acquired brain damage, such as stroke, the use of Lokomat® therapy can bring improvements in aspects such as gait speed and balance, among other parameters and report greater functional recovery in subacute patients with greater deterioration. Similarly, the use of another technological element such as the C-Mill® reports improvements in various aspects of ambulation and balance in gait treatments for stroke patients. Likewise, the impact on the person's recovery is not only beneficial for gait rehabilitation, but also improves the perception of well-being, which can be positive in the process of readaptation to daily life. The effect of both treatments for gait rehabilitation in adults with stroke and their impact on quality of life in the neurorehabilitation clinic will be studied. adults with stroke and their impact on quality of life at the Lescer neurorehabilitation clinic Lescer, Madrid (Spain). Participants will be assessed at baseline, 4 weeks, 8 weeks and 12 weeks.
Interventions
Sponsors
Universidad Pontificia de Salamanca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of stroke (haemorrhagic and/or ischaemic) by a specialist physician. . * Subjects who are cognitively capable and who sign the informed consent form.
Exclusion criteria
* Severe cognitive impairment (Mini-Mental State Examination \< 24.), or impairment that prevents correct understanding of the correct understanding of the messages and explanatory orders of the treatment and its conditions. * Diagnosis of concomitant neurological diseases and craniocerebral trauma. cranioencephalic trauma. * Other diseases that interfere with the gait process (e.g. disabling arthritis or arthrosis, other neurological diseases, other neurological diseases). disabling arthritis or osteoarthritis, other concomitant neurological diseases, etc.). \- Contraindications of the robotic tools themselves.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| quality of life scale | 12 weeks | QoL39 scale. 0 minimum - 100 maximum (higher scores mean a better outcome). |
| Spasticity index | 12 weeks | Tardieu scale 0 min - 5 max (higher scores mean a worse outcome). |
Countries
Spain
Contacts
Primary ContactJorge V Velázquez Saornil, PhD.
Outcome results
None listed